Scribe Therapeutics Inc (SCTX)

Currency in USD
34.92
+3.87(+12.46%)
Real-time Data·
Trading near 52-week High
SCTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.8835.00
52 wk Range
15.0035.00
Key Statistics
Prev. Close
31.05
Open
31.04
Day's Range
30.88-35
52 wk Range
15-35
Volume
90.98K
Average Volume (3m)
252.27K
1-Year Change
-
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.00
Upside
+40.32%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Scribe Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.00
(+40.32% Upside)

Earnings

Latest Release
12/06/2026
EPS / Forecast
-1.19 / --
Revenue / Forecast
2.23M / --
EPS Revisions
Last 90 days

SCTX Income Statement

Compare SCTX to Peers and Sector

Metrics to compare
SCTX
Peers
Sector
Relationship
P/E Ratio
−16.4x−3.5x−0.3x
PEG Ratio
-0.010.00
Price/Book
−3.7x6.6x2.6x
Price / LTM Sales
16.1x7.1x3.1x
Upside (Analyst Target)
61.0%434.3%48.5%
Fair Value Upside
Unlock21.1%6.3%Unlock

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
372.35K1.97%11.56M
Other Institutional Investors
19.70M98.03%611.67M
Public Companies & Retail Investors
0.000.00%0.00
Total
20.07M100.00%623.23M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Avoro Capital Advisors LLC16.37%3,088,88895,910
Andreessen Horowitz LLC16.34%3,082,72595,719

FAQ

What Is the Scribe Therapeutics (SCTX) Stock Price Today?

The Scribe Therapeutics stock price today is 34.92 USD.

What Stock Exchange Does Scribe Therapeutics Trade On?

Scribe Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Scribe Therapeutics?

The stock symbol for Scribe Therapeutics is "SCTX."

What Is the Scribe Therapeutics Market Cap?

As of today, Scribe Therapeutics market cap is 585.74M USD.

What Is Scribe Therapeutics's Earnings Per Share (TTM)?

The Scribe Therapeutics EPS (TTM) is -14.64.

From a Technical Analysis Perspective, Is SCTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Scribe Therapeutics Stock Split?

Scribe Therapeutics has split 0 times.

How Many Employees Does Scribe Therapeutics Have?

Scribe Therapeutics has 89 employees.

What is the current trading status of Scribe Therapeutics (SCTX)?

As of 20/08/2026, Scribe Therapeutics (SCTX) is trading at a price of 34.92 USD, with a previous close of 31.05 USD. The stock has fluctuated within a day range of 30.88 USD to 35.00 USD, while its 52-week range spans from 15.00 USD to 35.00 USD.

What Is Scribe Therapeutics (SCTX) Price Target According to Analysts?

The average 12-month price target for Scribe Therapeutics is 49.00 USD, with a high estimate of 60 USD and a low estimate of 37 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +40.32% Upside potential.

What Is the SCTX Premarket Price?

SCTX's last pre-market stock price is 31.87 USD. The pre-market share volume is 2,540.00, and the stock has decreased by 0.82, or 2.64%.

What Is the SCTX After Hours Price?

SCTX's last after hours stock price is 31.24 USD, the stock has decreased by 0.19, or 0.61%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.